Mira Pharmaceuticals (MIRA) Non Operating Investment Income (2025)

Mira Pharmaceuticals' (MIRA) quarterly Non Operating Investment Income came in at -$211268.0 in Q4 2025, down 220.0% quarter-over-quarter from $176056.0 in Q3 2025.

Mira Pharmaceuticals (MIRA) Non Operating Investment Income (2025) Analysis & Trends

Mira Pharmaceuticals has disclosed Non Operating Investment Income across 1 years of filings, most recently posting -$211268.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn -
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -
10 Mira Pharmaceuticals 22.73 Mn 11.70 Mn - -211,268.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -211,268.00
Dec 31, 2025 -211,268.00
Sep 30, 2025 176,056.00
Sep 30, 2025 176,056.00